1st Dec 2015 17:26
SKYEPHARMA PLC - CHANGE OF DIRECTORATE
LONDON, UK, 1 December, 2015 - Skyepharma PLC (LSE: SKP), the expert oral and inhalation drug development company, today announces that Mr Jean-Charles Tschudin has decided to step down as a Director of the Company, for personal reasons, with effect from 31 December 2015. Mr Tschudin was appointed to Skyepharma's Board as a Non-Executive Director in July 2007 and has served for almost eight and a half years.
Mr Tschudin will also stand down as Chairman of the Nomination and Governance Committee, Senior Independent Non-Executive Director and as a member of the Audit and Remuneration Committees with effect from the same date.
Mr Frank Condella, Chairman of the Company will take over as Chairman of the Nomination and Governance Committee. The appointment of a new Senior Independent Non-Executive Director will be made shortly.
As part of standard succession planning arrangements, the Company had already initiated a search for the appointment of an additional independent Non-Executive Director earlier in 2015. That search is advancing and an announcement will be made in due course.
Mr Condella, Chairman, commented, "On behalf of the Company, I would like to thank Jean-Charles for his support and valuable contributions to Board discussions over a period which has been transformational for the Company. We wish him all the very best for the future."
-Ends-
For further information, please contact:
Skyepharma PLC | |
Peter Grant, Chief Executive Officer Andrew Derodra, Chief Financial Officer | +44 207 881 0524 |
Jonathan Birt, Investor and Media Relations
| +44 786 036 1746 |
FTI Consulting | |
Julia Phillips/Rob Winder/Natalie Garland-Collins | +44 203 727 1000 |
N+1 Singer | |
Shaun Dobson/Gillian Martin/Jen Boorer | +44 207 496 3000 |
About Skyepharma
Skyepharma combines proven scientific expertise with validated proprietary drug delivery technologies to develop innovative oral and inhalation pharmaceutical products. The Group is eligible for revenues from 16 approved products in the areas of inhalation, oral, topical and injectable drug delivery as well as generating income from the development of further products and technology licenses. The products developed by the Group are marketed throughout the world by big pharma as well as speciality pharmaceutical companies. For more information, visit www.skyepharma.com
Related Shares:
SKP.L